Transactions
13
Insider / CYTOKINETICS INC
HENDERSON JOHN T
Director at CYTOKINETICS INC
- Company
- CYTOKINETICS INC
- Ticker
- CYTK
- First filing on record
- October 16, 2025
- Latest trade on record
- October 16, 2026
- SEC filings
- EDGAR ↗
HENDERSON JOHN T, Director at CYTOKINETICS INC, has disclosed 13 transactions in CYTK since October 16, 2025: 0 purchases (0 open-market buys) and 2 sales, worth about $2.4M at the reported prices. The latest was filed October 20, 2026, 4 days after the trade.
Open-market buys
0
Sales
2
Avg. disclosure lag
0.5d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months HENDERSON JOHN T made no purchases and 2 sales worth $2.1M, plus 10 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
HENDERSON JOHN T has traded 1 stock on record; the largest by dollars is CYTK.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 8 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 7 | 8,773 | $109K |
| M | Option exercise or conversion | 4 | 57,500 | $240K |
| S | Open-market sale | 2 | 28,750 | $2.1M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 9 | 0 | 1 · $1.5M |
| 2025 | 4 | 0 | 1 · $559K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| CYTK | Other A | October 16, 2026 | October 20, 2026 | 4d | 352 | $64 | $22K | Form 4 ↗ | ||
| CYTK | Other A | July 15, 2026 | July 16, 2026 | 1d | 272 | $83 | $22K | Form 4 ↗ | ||
| CYTK | Other A | May 27, 2026 | May 27, 2026 | 0d | 4,301 | — | — | derivative | Form 4 ↗ | |
| CYTK | Other A | May 27, 2026 | May 27, 2026 | 0d | 2,851 | — | — | Form 4 ↗ | ||
| CYTK | Option / conversion M | May 5, 2026 | May 5, 2026 | 0d | 20,000 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| CYTK | Sell S | May 5, 2026 | May 5, 2026 | 0d | 20,000 | $76 | $1.5M | 10b5-1 plan | Form 4 ↗ | |
| CYTK | Option / conversion M | May 5, 2026 | May 5, 2026 | 0d | 20,000 | $8 | $152K | 10b5-1 plan | Form 4 ↗ | |
| CYTK | Other A | April 15, 2026 | April 15, 2026 | 0d | 325 | $65 | $21K | Form 4 ↗ | ||
| CYTK | Other A | January 15, 2026 | January 16, 2026 | 1d | 334 | $63 | $21K | Form 4 ↗ | ||
| CYTK | Option / conversion M | December 2, 2025 | December 2, 2025 | 0d | 8,750 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| CYTK | Sell S | December 2, 2025 | December 2, 2025 | 0d | 8,750 | $64 | $559K | 10b5-1 plan | Form 4 ↗ | |
| CYTK | Option / conversion M | December 2, 2025 | December 2, 2025 | 0d | 8,750 | $10 | $88K | 10b5-1 plan | Form 4 ↗ | |
| CYTK | Other A | October 15, 2025 | October 16, 2025 | 1d | 338 | $63 | $21K | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 20, 2026 | Form 4 | 0001061983-26-000101 | 1 | published | EDGAR ↗ |
| July 16, 2026 | Form 4 | 0001061983-26-000080 | 1 | published | EDGAR ↗ |
| May 27, 2026 | Form 4 | 0001061983-26-000059 | 2 | published | EDGAR ↗ |
| May 5, 2026 | Form 4 | 0001061983-26-000048 | 3 | published | EDGAR ↗ |
| April 15, 2026 | Form 4 | 0001061983-26-000039 | 1 | published | EDGAR ↗ |
| January 16, 2026 | Form 4 | 0001061983-26-000005 | 1 | published | EDGAR ↗ |
| December 2, 2025 | Form 4 | 0001061983-25-000042 | 3 | published | EDGAR ↗ |
| October 16, 2025 | Form 4 | 0001061983-25-000012 | 1 | published | EDGAR ↗ |
Other insiders at CYTOKINETICS INC
- Callos Andrew EVP, Chief Commercial Officer 71 rows
- Malik Fady Ibraham EVP Research & Development 70 rows
- Blum Robert I President & CEO 52 rows
- Lee Sung EVP, Chief Financial Officer 38 rows
- Kaye Edward M. MD Director 17 rows
- WIERENGA WENDELL Director 16 rows
- Daly James M Director 8 rows
- Harrington Robert Arthur Director 8 rows
- Wysenski Nancy Director 7 rows
- PARSHALL B LYNNE Director 6 rows
Everyone on file, with contracts and lobbying under the company's name: CYTOKINETICS INC.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 8 | 13 | October 16, 2025 | October 20, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.